Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC By Ogkologos - July 9, 2025 479 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SERENA-6 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR How the history of medicine influenced our perception of cancer October 13, 2022 Registered Dietitian vs. Nutritionist March 3, 2021 Adjuvant Everolimus Does Not Improve Recurrence-Free Survival Among Patients with Renal... August 9, 2023 Distinct and Overlapping Pathways Contribute to the Efficacy of Nivolumab-Based Regimens... March 26, 2025 Load more HOT NEWS Snowboarder Wins Gold Medal At Winter Olympics After Beating Cancer What to Know About Cancer Care and Research for People 65+:... Severe mental illness linked to low attendance at cancer screening Cancer in My Community: Striving to Lead People to Cancer Care...
